Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-use safety study of ModraDoc006/r in advanced solid tumors
NL-OMON45294Phase 2Recruiting
- Sponsor
- Modra Pharmaceuticals
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ModraDoc006 and ritonavir in Nonhematologic neoplasms, sponsored by Modra Pharmaceuticals. Started May 2017; status: recruiting.
02
Drugs
ModraDoc006ritonavir
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON45294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45294.